Our previous findings in women with BC also suggested an increase in circulating levels of AngIV, whose actions are mediated by the AT4 receptor [20], and AT4 receptor ligands dose-dependently inhibit the catalytic activity of IRAP [23,24]. The gene discussed is LNPEP; the disease is breast cancer.